Kura Oncology, Inc.

KURA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001422143

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $738.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data; fortress balance sheet not computable: distress
Inputs computable	5 of 14
Graded from	filings received through Mar 5, 2026 240 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$10.27 2026-10-30; market equity $913.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates. Our pipeline consists of small molecules designed to target cancer signaling pathways and address significant unmet needs in oncology and hematology. 2025 was a pivotal year for our company.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 14.5						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(28.6%)	(6.6%)	14.5	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 38.9					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(2.37)	(0.35)	47.3	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	6.06x	2.92x	30.6	829	2025-12-31
Growth and financing, sleeve percentile 36.9					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	17.4%	2.2%	23.6	696	2025-12-31
Net share issuance, one year	9.4%	2.5%	50.2	631	2026-02-27

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 139,399,000 USD; Altman Z is not used

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	42.9%	7.3%	72
Distance from 52-week high	(24.5%)	(28.7%)	56
EBIT to enterprise value	(35.6%)	(1.4%)	17
Free cash flow yield	(7.7%)	(1.0%)	35
Book value to price	0.05	0.28	19
Sales to price	0.07	0.30	20
Composite equity issuance, five years	29.5%	20.5%	58
Relative strength against the sector, log excess return	0.15	(0.14)	72

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$70.2M
Operating cash flow, four quarters	-$111.8M
Months of runway	7.5
Days since last periodic filing	80 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$19.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-$303.6M	2025-12-31	2026-03-05	10-K	26-092567
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$278.4M	2025-12-31	2026-03-05	10-K	26-092567
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$297,000	2025-12-31	2026-03-05	10-K	26-092567
4	total debt	us-gaap:LongTermDebt	$9.7M	2025-12-31	2026-03-05	10-K	26-092567
5	book equity	us-gaap:StockholdersEquity	$174.1M	2025-12-31	2026-03-05	10-K	26-092567
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$149.1M	2025-12-31	2026-03-05	10-K	26-092567
7	total debt	us-gaap:LongTermDebt	$9.5M	2024-12-31	2025-02-28	10-K	25-029975
8	book equity	us-gaap:StockholdersEquity	$413.6M	2024-12-31	2026-03-05	10-K	26-092567
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$224.5M	2024-12-31	2026-03-05	10-K	26-092567
10	net income	us-gaap:NetIncomeLoss	-$278.7M	2025-12-31	2026-03-05	10-K	26-092567
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$64.1M	2025-12-31	2026-03-05	10-K	26-092567
12	assets	us-gaap:Assets	$738.4M	2025-12-31	2026-03-05	10-K	26-092567
13	assets	us-gaap:Assets	$760.2M	2024-12-31	2026-03-05	10-K	26-092567
14	current assets	us-gaap:AssetsCurrent	$708.7M	2025-12-31	2026-03-05	10-K	26-092567
15	current liabilities	us-gaap:LiabilitiesCurrent	$117.0M	2025-12-31	2026-03-05	10-K	26-092567
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2025-12-31	2026-03-05	10-K	26-092567
17	liabilities	us-gaap:Liabilities	$564.2M	2025-12-31	2026-03-05	10-K	26-092567
18	depreciation amortization	us-gaap:Depreciation	$1.0M	2025-12-31	2026-03-05	10-K	26-092567
19	operating income	us-gaap:OperatingIncomeLoss	-$23,907	2014-12-31	2015-02-27	10-K	15-001429
20	interest expense	us-gaap:InterestExpense	$6,827	2014-12-31	2015-02-27	10-K	15-001429
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$67.5M	2025-12-31	2026-03-05	10-K	26-092567
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$53.9M	2024-12-31	2026-03-05	10-K	26-092567
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.6M	2025-12-31	2026-03-05	10-K	26-092567
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$134.3M	2024-12-31	2026-03-05	10-K	26-092567
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$472,000	2024-12-31	2026-03-05	10-K	26-092567
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$124.8M	2023-12-31	2026-03-05	10-K	26-092567
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$168,000	2023-12-31	2026-03-05	10-K	26-092567
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$110.1M	2022-12-31	2025-02-28	10-K	25-029975
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$626,000	2022-12-31	2025-02-28	10-K	25-029975
30	current assets	us-gaap:AssetsCurrent	$744.8M	2024-12-31	2026-03-05	10-K	26-092567
31	current liabilities	us-gaap:LiabilitiesCurrent	$78.7M	2024-12-31	2026-03-05	10-K	26-092567
32	assets	us-gaap:Assets	$448.9M	2023-12-31	2025-02-28	10-K	25-029975
33	assets	us-gaap:Assets	$456.3M	2022-12-31	2024-02-27	10-K	24-021094
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,329,759	2026-02-27	2026-03-05	10-K	26-092567
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	80,754,961	2025-02-20	2025-02-28	10-K	25-029975

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.